BioNTech SE (BNTX)
103.76
+0.88
(+0.86%)
USD |
NASDAQ |
Sep 04, 16:00
103.76
0.00 (0.00%)
Pre-Market: 20:00
BioNTech Research and Development Expense (Quarterly) : 514.38M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 514.38M |
| March 31, 2026 | 651.65M |
| December 31, 2025 | 588.25M |
| September 30, 2025 | 660.04M |
| June 30, 2025 | 577.04M |
| March 31, 2025 | 553.17M |
| December 31, 2024 | 652.60M |
| September 30, 2024 | 604.53M |
| June 30, 2024 | 629.34M |
| March 31, 2024 | 550.82M |
| December 31, 2023 | 621.38M |
| September 30, 2023 | 541.63M |
| June 30, 2023 | 406.39M |
| Date | Value |
|---|---|
| March 31, 2023 | 358.36M |
| December 31, 2022 | 520.02M |
| September 30, 2022 | 344.10M |
| June 30, 2022 | 425.28M |
| March 31, 2022 | 320.62M |
| December 31, 2021 | 310.33M |
| September 30, 2021 | 306.94M |
| June 30, 2021 | 242.45M |
| March 31, 2021 | 260.41M |
| December 31, 2020 | 295.79M |
| September 30, 2020 | 257.53M |
| June 30, 2020 | 97.32M |
| March 31, 2020 | 63.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 3.020M |
| Mereo BioPharma Group Plc | 1.811M |
| MediGene AG | -- |